NASDAQ:ATXS - Catabasis Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $23.75
  • Forecasted Upside: 148.69 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$9.55
▼ -0.39 (-3.92%)

This chart shows the closing price for ATXS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Catabasis Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATXS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATXS

Analyst Price Target is $23.75
▲ +148.69% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Catabasis Pharmaceuticals in the last 3 months. The average price target is $23.75, with a high forecast of $36.00 and a low forecast of $13.00. The average price target represents a 148.69% upside from the last price of $9.55.

This chart shows the closing price for ATXS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Catabasis Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/20/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/2/2021WedbushInitiated CoverageOutperform$16.00High
8/25/2021HC WainwrightUpgradeNeutral ➝ Buy$13.00Low
5/12/2021LADENBURG THALM/SH SHInitiated CoverageBuy$36.00High
3/11/2021OppenheimerUpgradeMarket Perform ➝ Outperform$30.00High
2/1/2021HC WainwrightReiterated RatingHoldLow
11/2/2020WedbushDowngradeOutperform ➝ NeutralMedium
10/27/2020HC WainwrightDowngradeBuy ➝ NeutralN/A
10/27/2020OppenheimerDowngradeOutperform ➝ Market PerformN/A
10/1/2020HC WainwrightInitiated CoverageBuy$144.00 ➝ $144.00High
9/15/2020OppenheimerReiterated RatingBuy$360.00High
8/20/2020WedbushReiterated RatingBuy$90.00Low
6/11/2020WedbushReiterated RatingBuy$90.00Medium
4/19/2020WedbushReiterated RatingBuy$90.00Medium
3/10/2020OppenheimerReiterated RatingBuy$360.00High
3/10/2020WedbushReiterated RatingBuy$90.00High
1/8/2020WedbushReiterated RatingBuy$108.00Medium
12/16/2019WedbushReiterated RatingBuy$108.00Low
11/8/2019CitigroupLower Price Target$432.00 ➝ $360.00High
7/29/2019WedbushReiterated RatingOutperform$108.00High
6/24/2019WedbushSet Price TargetBuy$108.00High
5/17/2019WedbushReiterated RatingBuy$108.00Medium
3/18/2019WedbushReiterated RatingBuy$120.00Low
1/29/2019WedbushSet Price TargetBuy$168.00N/A
1/14/2019OppenheimerBoost Price TargetOutperform$42.00 ➝ $462.00High
11/14/2018OppenheimerSet Price TargetBuy$420.00Low
8/10/2018CitigroupLower Price TargetBuy ➝ Buy$150.00 ➝ $90.00Low
8/9/2018WedbushSet Price TargetBuy$180.00Low
3/20/2018WedbushBoost Price TargetOutperform ➝ Outperform$300.00 ➝ $360.00Low
2/14/2018WedbushReiterated RatingOutperform$300.00 ➝ $240.00High
12/15/2017WedbushReiterated RatingOutperform$240.00Low
11/20/2017CitigroupUpgradeNeutral ➝ Buy$180.00N/A
10/6/2017CowenReiterated RatingMarket Perform$120.00N/A
10/5/2017CIBCReiterated RatingOutperform ➝ Outperform$240.00 ➝ $420.00N/A
10/5/2017CitigroupSet Price TargetHold$90.00 ➝ $210.00N/A
10/5/2017OppenheimerBoost Price TargetOutperform$240.00 ➝ $420.00N/A
9/29/2017CitigroupReiterated RatingHold$90.00Low
8/15/2017OppenheimerLower Price TargetOutperform$540.00 ➝ $240.00High
8/14/2017HC WainwrightBoost Price TargetBuy$480.00 ➝ $540.00Medium
6/21/2017WedbushReiterated RatingOutperform$240.00High
5/15/2017WedbushReiterated RatingOurperform$240.00High
5/15/2017OppenheimerReiterated RatingOutperform$660.00 ➝ $540.00Medium
4/26/2017WedbushReiterated RatingOutperform$240.00Low
3/21/2017HC WainwrightReiterated RatingBuy$840.00 ➝ $480.00Low
3/20/2017WedbushReiterated RatingOutperform$240.00High
3/18/2017OppenheimerSet Price TargetBuy$660.00High
3/14/2017WedbushReiterated RatingOutperform$240.00Medium
2/2/2017WedbushReiterated RatingOutperform$900.00 ➝ $240.00N/A
2/1/2017CitigroupDowngradeBuy ➝ NeutralN/A
2/1/2017CowenDowngradeOutperform ➝ Market Perform$240.00N/A
1/31/2017OppenheimerSet Price TargetBuy$1,080.00 ➝ $660.00N/A
1/6/2017WedbushReiterated RatingOutperform$900.00N/A
12/22/2016HC WainwrightInitiated CoverageBuy$840.00N/A
12/7/2016WedbushReiterated RatingOutperform$900.00N/A
11/14/2016WedbushReiterated RatingOutperform$900.00 ➝ $1,020.00N/A
10/13/2016WedbushReiterated RatingOutperform$1,020.00N/A
9/29/2016WedbushReiterated RatingOutperform$1,020.00N/A
(Data available from 9/20/2016 forward)

News Sentiment Rating

-0.01 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/24/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/22/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/22/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/21/2021
  • 1 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/20/2021

Current Sentiment

  • 1 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Catabasis Pharmaceuticals logo
Catabasis Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is edasalonexent, which is intended for the treatment of Duchenne muscular dystrophy. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.
Read More

Today's Range

Now: $9.55
Low: $9.50
High: $9.95

50 Day Range

MA: $10.05
Low: $7.32
High: $45.48

52 Week Range

Now: $9.55
Low: $6.31
High: $47.82

Volume

271,500 shs

Average Volume

477,167 shs

Market Capitalization

$37.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.66

Frequently Asked Questions

What sell-side analysts currently cover shares of Catabasis Pharmaceuticals?

The following Wall Street analysts have issued stock ratings on Catabasis Pharmaceuticals in the last year: HC Wainwright, LADENBURG THALM/SH SH, Oppenheimer Holdings Inc., Wedbush, and Zacks Investment Research.
View the latest analyst ratings for ATXS.

What is the current price target for Catabasis Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for Catabasis Pharmaceuticals in the last year. Their average twelve-month price target is $23.75, suggesting a possible upside of 148.7%. LADENBURG THALM/SH SH has the highest price target set, predicting ATXS will reach $36.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $13.00 for Catabasis Pharmaceuticals in the next year.
View the latest price targets for ATXS.

What is the current consensus analyst rating for Catabasis Pharmaceuticals?

Catabasis Pharmaceuticals currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ATXS will outperform the market and that investors should add to their positions of Catabasis Pharmaceuticals.
View the latest ratings for ATXS.

What other companies compete with Catabasis Pharmaceuticals?

How do I contact Catabasis Pharmaceuticals' investor relations team?

Catabasis Pharmaceuticals' physical mailing address is 100 High StreetFloor 28, Boston MA, 02110. The biotechnology company's listed phone number is 617-349-1971 and its investor relations email address is [email protected] The official website for Catabasis Pharmaceuticals is www.catabasis.com.